Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? (Q35954640)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? |
scientific article |
Statements
1 reference
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? (English)
1 reference
Elisabeth Hjardem
1 reference
Mikkel Østergaard
1 reference
Jan Pødenphant
1 reference
Ulrik Tarp
1 reference
Lis Smedegaard Andersen
1 reference
Jette Bing
1 reference
Elisabeth Peen
1 reference
Vibeke Stevenius Ringsdal
1 reference
Anne Rødgaard
1 reference
Jens Skøt
1 reference
Annette Hansen
1 reference
Hans Henrik Mogensen
1 reference
Janne Unkerskov
1 reference
27 March 2007
1 reference
1 reference
1184-1189
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference